This is of particular importance, because targeting this channel has been discussed as an alternative drug target to restore Cl− secretion in cystic fibrosis patients due to defective cystic fibrosis transmembrane conductance regulator function (Danahay et al., 2020). The gene discussed is CFTR; the disease is cystic fibrosis.